TGTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
TG THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$53.30−0.67 (-1.24%)
Close on Oct 19, 2026
- Market cap
- $8.38B
- P/E (TTM)
- 19.5
- Dividend yield
- –
TG THERAPEUTICS, INC. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product [Member] | $235.79M | $201.31M | $189.11M | $159.32M | $138.84M | $119.66M | $107.35M | $83.30M | $72.60M | $50.49M | $43.14M | $25.07M | 98.1% | +69.8% |
| License [Member] | $4.54M | $3.61M | $3.46M | $2.39M | $2.31M | $1.20M | $838.00K | $582.00K | $870.00K | $12.99M | $834.00K | $140.75M | 1.9% | +97.0% |
| License Revenue [Member] | $4.54M | $3.61M | – | $2.39M | $2.31M | $1.20M | $38.00K | $582.00K | $870.00K | $38.00K | $39.00K | $140.04M | 1.9% | +97.0% |
| Royalty [Member] | – | – | – | – | – | $605.00K | $389.00K | $229.00K | $150.00K | $33.00K | $0 | $0 | – | – |
| Other Revenue [Member] | – | – | – | – | – | $558.00K | $411.00K | $315.00K | $682.00K | $415.00K | $795.00K | $709.00K | – | – |
| Milestone [Member] | – | – | – | – | – | $0 | $0 | $0 | $0 | $12.50M | $0 | $0 | – | – |
By region
From the segment and revenue-disaggregation notes of Tg Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.